Cosmos Holdings

COSM

Market cap $12.2M

Cosmos Health expands its Sky Premium Life partnership with Pharma Cell in Albania, with average monthly orders already exceeding 4,500 units, and projected to exceed 54,000 annually Products are distributed across Albania and recommended by doctors and healthcare professionals, supporting broad consumer access Expansion builds on the partnership launched in April 2025 and reflects Sky Premium Life's continued global growth CHICAGO, July 20, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”)  (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced an expansion of its partnership with Pharma Cell for the distribution of its Sky Premium Life brand in Albania. Building on the partnership the companies launched in April 2025, and reflecting the strong reception of Sky Premium Life in the Albanian market, the Company anticipates that orders under the expanded relationship will exceed 54,000 units on an annualized basis, with average monthly orders already exceeding 4,500 units.

CHICAGO, July 17, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 274,000 shares of its common stock in the open market at an average price of approximately $0.2554 per share. The Company has now repurchased a total of 5,112,000 shares for approximately $1.11 million under its previously announced share repurchase program of up to $5 million.

CHICAGO, July 16, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”)  (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 250,000 shares of its common stock in the open market at an average price of approximately $0.2782 per share. The Company has now repurchased a total of 4,838,000 shares for approximately $1.04 million under its previously announced share repurchase program of up to $5 million.

CHICAGO, July 15, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 100,000 shares of its common stock in the open market at an average price of approximately $0.2928 per share. The Company has now repurchased a total of 4,588,000 shares for approximately $970,000 under its previously announced share repurchase program of up to $5 million.

CHICAGO, July 14, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 133,000 shares of its common stock in the open market at an average price of approximately $0.298 per share. The Company has now repurchased a total of approximately 4,488,000 shares for approximately $941,000 under its previously announced share repurchase program of up to $5 million.

CHICAGO, July 13, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 215,000 shares of its common stock in the open market at an average price of approximately $0.325 per share. The Company has now repurchased a total of 4,355,000 shares for approximately $901,000 under its previously announced share repurchase program of up to $5 million.

Cosmos Health will supply DIABIT-IS X (sitagliptin), while Libytec handles distribution and promotion in Greece Five-year agreement expected to contribute to revenue and cash-flow visibility As a prescription medicine, DIABIT-IS X is expected to be accessible to patients through Greece's national health insurance system, broadening its potential reach DIABIT-IS X is a generic alternative to Merck's Januvia®, which with Janumet® generated approximately $4.5 billion in combined global sales in 2022 Positions Cosmos Health in the large and established European sitagliptin market CHICAGO, July 13, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has entered into an agreement for the commercialization of its type-2 diabetes medication DIABIT-IS X (sitagliptin phosphate) in the Greek market, through a distribution and promotion partnership with Libytec Pharmaceutical S.A. ("Libytec").

Subscription model already launched with NOOR Collagen in the United States Early data shows a repeat purchase rate above 60% at high margins in excess of 50% Model is designed to drive stronger loyalty, greater lifetime value, and more predictable cash-flow visibility Company plans to extend the subscription model to additional Cosmos Health products globally, with further initiatives already underway CHICAGO, July 10, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has launched a subscription-based purchasing model for its proprietary consumer health brands. The model is currently live with NOOR Collagen in the United States, with encouraging early results that include a repeat purchase rate above 60% and margins in excess of 50%.

CHICAGO, July 09, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 80,000 shares of its common stock in the open market at an average price of approximately $0.2503 per share. The Company has now repurchased a total of 4,140,000 shares for approximately $831,000 under its previously announced share repurchase program of up to $5 million.

CHICAGO, July 08, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 190,000 shares of its common stock in the open market at an average price of approximately $0.2805 per share. The Company has now repurchased a total of 4,060,000 shares for approximately $811,000 under its previously announced share repurchase program of up to $5 million.